PRO132365, RG3502, T-DM1, trastuzumab-MCC-DM1, Kadcyla

Human

CSB111A pdf (datasheet)

100 µg

$455.00 BUY

1.0 mg/ml

Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-microtubule agent, DM1 (a maytansine derivative)--to produce cell cycle arrest and apoptosis. Trastuzumab emtansine is marketed under the brand name Kadcyla and is indicated for use in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment. The FDA label has two precautions. First that trastuzumab emtansine and trastuzumab cannot be interchanged. Second that there is a black box warning of serious side effects such as hepatotoxicity, embryo-fetal toxicity, and cardiac toxicity.

ERBB2

P04626

> 95% as determined by SDS-PAGE

Human Receptor tyrosine-protein kinase erbB-2 (ERBB2)

Human

IgG1 Kappa light chain

PBS, pH 7.5

ELISA, FS

Store at -20°C to -80°C for up to 1 year